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Ten lines of transgenic mice secreting transmissible gastroenteritis coronavirus (TGEV) neutralizing re-
combinant monoclonal antibodies (rMAbs) into the milk were generated. The rMAb light- and heavy-chain
genes were assembled by fusing the genes encoding the variable modules of the murine MAb 6A.C3, which
binds an interspecies conserved coronavirus epitope essential for virus infectivity, and a constant module from
a porcine myeloma with the immunoglobulin A (IgA) isotype. The chimeric antibody led to dimer formation in
the presence of J chain. The neutralization specific activity of the recombinant antibody produced in transiently
or stably transformed cells was 50-fold higher than that of a monomeric rMAb with the IgG1 isotype and an
identical binding site. This rMAb had titers of up to 104 by radioimmunoassay (RIA) and neutralized virus
infectivity up to 104-fold. Of 23 transgenic mice, 17 integrated both light and heavy chains, and at least 10 of
them transmitted both genes to the progeny, leading to 100% of animals secreting functional TGEV neutral-
izing antibody during lactation. Selected mice produced milk with TGEV-specific antibody titers higher than
106 as determined by RIA, neutralized virus infectivity by 106-fold, and produced up to 6 mg of antibody per
ml. Antibody expression levels were transgene copy number independent and integration site dependent.
Comicroinjection of the genomic b-lactoglobulin gene with rMAb light- and heavy-chain genes led to the
generation of transgenic mice carrying the three transgenes. The highest antibody titers were produced by
transgenic mice that had integrated the antibody and b-lactoglobulin genes, although the number of transgenic
animals generated does not allow a definitive conclusion on the enhancing effect of b-lactoglobulin cointegra-
tion. This approach may lead to the generation of transgenic animals providing lactogenic immunity to their
progeny against enteric pathogens.
The secretory immunoglobulin A (IgA) provides the initial
immunologic barrier against most pathogens that invade the
body at mucosal surfaces (46). This is especially true for vi-
ruses, since resistance to infection has been strongly correlated
with the presence of specific IgA antibody in mucosal secre-
tions (4). At mucosal surfaces, IgA antibodies are particularly
stable and, since they are multivalent, might be more protec-
tive than IgG (26). The neutralization of viruses by immuno-
globulins (Igs) is thought to result from the binding of antibody
to virion attachment proteins, preventing their adherence to
epithelial cells. In addition, mucosal antibody interacts intra-
cellularly with viruses, preventing their replication, possibly by
interfering with virus assembly (34).
Transmissible gastroenteritis coronavirus (TGEV) infects
both enteric and respiratory tissues and causes a mortality
close to 100% when newborn pigs are infected (41). The major
antigenic sites of TGEV involved in the induction of virus
neutralizing antibodies are located in the globular portion of
the spike (S) protein (13, 15, 20). Investigations by our labo-
ratory into the mechanisms of TGEV neutralization (47) and
antigenic and genetic variability (17, 42, 43) have led to the
identification of a mouse monoclonal antibody (MAb) which
neutralized all the TGEV isolates tested and also neutralized
TGEV-related coronaviruses which infect at least three animal
species: pigs, dogs, and cats. This MAb, 6A.C3, probably binds
to an epitope essential for virus replication, since no neutral-
ization escape mutants appeared when it was used (20).
The immune response to TGEV has been characterized (3,
5, 49), and full protection against TGEV can be provided by
lactogenic immunity from immune sows (41). It has also been
shown that the passive oral administration of serum elicited by
recombinant adenoviruses expressing the spike protein com-
pletely protects piglets against virulent-virus challenge (48).
Conventional approaches such as lactogenic immunity and
artificial feeding may target the antibody to epithelial surfaces,
providing protection against enteric virus infections (41). Al-
ternatively, transgenic animals secreting virus neutralizing
antibodies into their milk during lactation should provide im-
mediate protection to piglets against enteric coronavirus infec-
tion. The mammary gland expression system is by nature very
suitable for the production of proteins that function in the
gastrointestinal tract and can be orally administered (31). In
this paper, we describe the engineering of a recombinant
TGEV neutralizing MAb with a porcine IgA isotype and the
comparison of its specific neutralizing activity with a recombi-
nant monomeric antibody having identical variable modules
and an IgG1 isotype.
We constructed transgenic mice carrying two expression cas-
settes containing the cDNA sequences encoding the heavy and
light chains of a chimeric IgA and gene expression regulatory
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sequences derived from the b-lactoglobulin (BLG) gene, to
target the recombinant IgA (rIgA) synthesis specifically to the
mammary gland. The effect of comicroinjecting the antibody
expression cassettes with BLG genomic DNA on expression
levels was studied. Transgenic mice that secrete high-titer virus
neutralizing rIgA into their milk have been obtained. This
strategy may be a general approach to protect against enteric
infections of newborns.
MATERIALS AND METHODS
Cells and viruses. Swine testis (ST) cells (35), simian virus 40 (SV40)-trans-
formed monkey kidney COS-1 cells (ATCC CRL-1650), nonsecreting murine
myeloma Sp2/0 cells (ATCC, CRL-1581), and MAb 6A.C3-secreting (14, 23) and
S2.1 IgA-secreting porcine hybridoma cells (24) were grown in Dulbecco’s mod-
ified Eagle’s medium supplemented with fetal calf serum. TGEV PUR46-MAD
(20) was grown, purified, and subjected to titer determination in ST cells as
described previously (23).
RIA, virus neutralization, and Western blot analysis. The rIgA collected from
supernatants of stably transformed Sp2/0 cells was purified by anion-exchange
high-pressure liquid chromatography and analyzed on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels (linear gradient from 5 to
20% polyacrylamide). The procedures for radioimmunoassay (RIA), virus neu-
tralization, and Western blotting have been described previously (14). The an-
tibody titer as determined by RIA was defined as the reverse of the maximum
antibody dilution giving a binding to TGEV threefold higher than the back-
ground. The neutralization index was defined as the log of the ratio of the PFU
after virus incubation in the presence of medium or the indicated MAb. All the
antisera were diluted 1:1,000 in phosphate-buffered saline containing 0.3% bo-
vine serum albumin and 0.1% Tween 20. The antisera used to develop the RIA
to detect recombinant mouse-human (rMH) antibodies were rabbit anti-human
kappa chain and rabbit anti-human IgG (Cappel). To detect recombinant mouse-
swine (rMS) antibodies, rabbit anti-swine IgA (Bethyl Laboratories, Inc.) was
used. To detect MAb 6A.C3, rabbit anti-mouse Ig (Cappel) was used.
The rabbit anti-J chain antiserum used to detect the J chain was a gift of
R. M. E. Parkhouse (Institute for Animal Health) and has been previously
characterized (25, 40).
To compare the neutralizing activity of rMH IgG with that of rMS IgA, the
same antiserum [goat anti-mouse F(ab9)2] was used. The neutralizing activities of
recombinant MAb dilutions with the same RIA titer were compared.
RNA extraction. Total cytoplasmic RNA from S2.1 hybridoma cells was pre-
pared by lysing 4 3 106 cells in 200 ml of TSM buffer (0.01 M Tris-hydrochloride
[pH 7.6], 0.15 M NaCl, 5 mM MgCl2) with 0.2% Nonidet P-40 and pelleting the
nuclei by centrifugation at 13,000 3 g for 30 s. RNA was isolated by the addition
of 200 ml of urea-SDS lysis buffer (8 M urea, 1.5% SDS, 15 mM EDTA, 0.24 M
NaCl, 0.04 M Tris-hydrochloride [pH 7.6]) followed by vigorous vortexing and
phenol-chloroform extraction. Poly(A)1 mRNA was isolated with the PolyAT-
tract mRNA Isolation System (Promega).
Synthesis of cDNAs encoding the constant modules of porcine Ig k and a
chains. To clone the porcine IgA constant (C) module, two cDNAs encoding the
constant light (CL) (Fig. 1A) and constant heavy (CH) (Fig. 1B) chains were
synthesized from poly(A)1 mRNA isolated from S2.1 hybridoma cells by reverse
transcriptase PCR (RT-PCR) with specific primers. The 59-end oligonucleotide
corresponding to the first porcine CL module nucleotides and the 39-end oligo-
nucleotide complementary to the 39 untranslated region contained ClaI and
BamHI restriction endonuclease sites, respectively. The 59-end oligonucleotide
corresponding to the first porcine CH module nucleotides and the 39-end oligo-
nucleotide complementary to the 39 untranslated region contained ApaI and
BamHI restriction endonuclease sites, respectively. All the fragments were
cloned into Bluescript SK2 (Stratagene), and their sequences were verified by
direct sequencing (Sequenase 2.0). The primers used in porcine IgA ampli-
fication were: flanking 59 CH, 59-GAAACGGGCCCCAAAATCTTCCCAC-39,
flanking 39 CH, 59-GCGGGATCCTTTATTCGAGGGGCG-39, flanking 59 CL,
59-CCGTATCGATCTTCCCGCCATCG-39, flanking 39 CL, 59-GCAAGGATC
CCTTTCACATTTATTC-39. The primers were designed on the basis of cDNA
sequences previously reported for porcine a CH (7) and k CL (29) modules.
Avian myeloblastosis virus RT (Seikagaku America, Inc.) was used at 0.4 U/ml,
and Taq polymerase (Perkin Elmer) was used at 0.03 U/ml. Amplifications were
performed in a GeneAmp PCR system 9600 apparatus.
Sequencing and characterization of cDNAs encoding porcine IgA a and k
chains. The cDNA clones encoding the C modules of light (L) and heavy (H)
chains from porcine IgA were sequenced by oligodeoxynucleotide primer exten-
sion and dideoxynucleotide chain termination procedures (44), using a previously
described method (18). To sequence porcine IgA L and H-chain genes, the
following primers were used: CL, 59-CCGTATCGATCTTCCCGCCATCG-39;
CL, 59-GCAAGGATCCCTTTCACATTTATTC-39; CL, 59-CAGGAATGAGT
GTGAGGC-39; CH, 59-GAAACGGGCCCCAAAATCTTCCCAC-39, CH, 59-G
CGGGATCCTTTATTCGAGGGGCG-39; CH, 59-GTGGCCTGAAAAAATC
CG-39; CH, 59-CCACCTGCTGCCGCCGCC-39; CH, 59-CACGCGTGGGGGA
CGCC-39; CH, 59-CGAGGACTGGAAGCAGGG-39. The cDNA sequences
were compared with other Ig sequences by using Kabat’s database and the
computer programs of the Genetics Computer Group (University of Wisconsin).
Construction of Ig expression plasmids. The chimeric mouse-porcine L-chain
expression vector was engineered (Fig. 1A) by ligating the SalI-ClaI VL fragment
amplified by RT-PCR from mouse MAb 6A.C3 mRNA (8) to the ClaI-BamHI
CL module obtained by RT-PCR from porcine MAb S2.1 mRNA and cloning the
resulting cDNA into expression plasmid pING2016E-gpt (33, 55), previously
digested with SalI and BamHI. The resulting plasmid was designated pINSLC6A.
The chimeric mouse-porcine H-chain expression vector was engineered (Fig.
1B) by ligating the BamHI-ApaI VH fragment amplified by RT-PCR from mouse
MAb 6A.C3 mRNA (8) to the ApaI-BamHI CH module (33, 55) obtained by
RT-PCR from porcine MAb S2.1 mRNA and cloning the resulting cDNA into
expression plasmid pING2003E-neo previously digested with BamHI. The re-
sulting plasmid was designated pINSHC6A.
Transformation of Sp2/0 myeloma cells with Ig gene expression plasmids.
To express rMS IgA antibody, the L-chain pINSLC6A (5 mg) and H-chain
pINSHC6A (5 mg) plasmids were cotransfected. To express rMH IgG1 antibody,
L-chain pINLC6A (5 mg) and H-chain pINHC6A (5 mg) plasmids (previously
described [8]) were linearized at unique restriction sites after the 39 ends of Ig
genes (BglII for pINSLC6A and pINLC6A and AatII for pINSHC6A and
pINHC6A) and were cotransfected into 107 Sp2/0 cells by electroporation (39).
The cells were seeded in an M-24 microplate at 4 3 105 per well. Transformants
were selected in the presence of the antibiotic Geneticin (G418; 0.8 mg/ml;
Boehringer Mannheim). The supernatants from all the wells were positive for
TGEV-specific antibodies by RIA. The cells showing the highest expression level
were cloned twice by limiting dilution.
Transient expression of Ig genes in COS-1 cells. COS-1 (8 3 105) cells were
transfected by the Lipofectin (GIBCO BRL) method with 5 mg of circular DNA
of the same expression vectors used in the stable transformation. Antibody levels
were evaluated by RIA and neutralization in supernatants harvested at the
indicated times posttransfection.
BLG constructs and plasmids. The unmodified BLG construct pSS1tgXS has
been described previously (1, 21, 45) and comprises 4.3 kb of 59-flanking se-
quences, the 4.9-kb transcription unit, and 1.7 kb of 39-flanking sequences of the
B allele of sheep BLG (2). To generate the expression cassette pBJ41 (Fig. 2), an
EcoRV cloning site was created by introducing a linker between the PvuII sites
of exons 1 and 5 of the BLG gene. Introns 5 and 6 were removed. This plasmid
also includes 4.3 kb of BLG 59-flanking sequences (from SalI) and 1.7 kb of BLG
39-flanking sequences (to XbaI) from clone SS1 (1, 21, 45) cloned into pUC19.
pBJ41 contains transcription initiation and polyadenylation sites but does not
contain a translation initiation site. The cDNAs fragments encoding the chimeric
L and H chains of rIgA were cloned separately at the unique EcoRV site of
plasmid pBJ41. Constructs to express murine-porcine chimeric L chain (BLG-
SLC) and murine-porcine chimeric H chain (BLG-SHC) under the control of
BLG regulatory sequences were obtained.
Generation of transgenic mice. SalI-XbaI digestion of the plasmid vectors
released the 10.5-kb genomic BLG, the 7.7-kb BLG-SLC, and the 8.2-kb BLG-
SHC fragments for microinjection. These fragments were purified from a sodium
chloride step gradient as described previously (19). BLG2 transgenic mice were
generated by coinjecting BLG-SLC and BLG-SHC fragments in a 1:1 molar
ratio. BLG1 transgenic mice were generated by coinjecting BLG-SLC, BLG-
SHC, and 10.5-kb BLG fragments in a 1:1:1 molar ratio. Pronuclear-stage eggs
were obtained from superovulated C57BL/6 3 CBAF1 females after mating with
F1 males. DNA (2 or 3.5 mg/ml) was injected into either pronucleus by standard
techniques. The injected eggs were cultured overnight, and two-cell embryos
were transferred into the oviducts of pseudopregnant Swiss recipients. Trans-
genic lines were propagated by mating to (C57BL/6 3 CBAF1) F1 hybrids or to
B6CBAF1 mice.
DNA analysis. Genomic DNA was prepared from a tail biopsy specimen,
obtained from each mouse at weaning, by proteinase K digestion followed by
phenol-chloroform extraction and ethanol precipitation, as described previously
(30). Transgenic mice were identified by a PCR assay. To detect the BLG-SLC
transgene, we used BLG1 (59-GGGCTGGCTGGCCTGCATGC-39) and LKV1
(59-CCGTCCCAGATCCACTGCC-39) primers, which hybridize with BLG 59-
regulatory sequences and the VL module of SLC, respectively, defining a 390-bp
region present only in transgenic animals. To detect the BLG-SHC transgene, we
used BLG1 and HV1 (59-GGCCTTGCCCTGGAACTTCGGG-39) primers,
which hybridize with BLG 59-regulatory sequences and the VH module of SHC,
respectively, defining a 370-bp region. To detect genomic BLG sequences, we
used BLG1 and BLG3 (59-GAAGCCAGCCCTGCCAACACC-39) primers,
which hybridize with 59-regulatory sequences and intron 1 sequences, respec-
tively, defining a 400 bp region. Taq polymerase (Perkin Elmer) was used at 0.03
U/ml. Amplifications were performed in a GeneAmp PCR system 9600 apparatus.
EcoRI-cleaved DNA (10 mg) was analyzed by agarose gel electrophoresis,
Southern blotting, and hybridization with 32P-labeled DNA probes, using ran-
dom primers as recommended by the supplier (DECAprimeII DNA-labeling kit;
Ambion). The DNA fragment used to probe the blot was specific for the com-
mon BLG promoter and therefore detected all three genes simultaneously,
allowing the copy numbers of the three genes in each animal to be compared on
the same Southern blot. The results were quantified with a Molecular Dynamics
PhosphorImager. The transgene copy number was determined by comparison
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FIG. 1. Cloning of Ig L and H chain cDNAs into expression vectors. (A) Cloning of the recombinant mouse-porcine L-chain cDNA. Poly(A)1 RNA from hybridoma
cells secreting MAb 6A.C3 was used as the template for an RT-PCR to obtain the cDNA encoding the VL module. SalI and ClaI restriction sites were introduced into
VL module cDNA at the 59 and 39 ends, respectively, to facilitate the cloning of the RT-PCR-derived cDNA into pBluescript SK2. Poly(A)1 RNA from porcine
hybridoma cells secreting MAb S2.1 of the IgA isotype was used as the template for an RT-PCR to obtain the cDNA encoding the CL module. ClaI and BamHI
restriction sites were introduced into CL module cDNA at the 59 and 39 ends, respectively, to facilitate the cloning of the RT-PCR derived cDNA into pBluescript SK2.
The resulting VL and CL fragments were joined at the ClaI restriction site and cloned into the expression vector pING2016E-gpt by using the SalI and BamHI sites,
yielding plasmid pINSLC6A. (B) Cloning of the recombinant mouse-porcine H-chain cDNA. Poly(A)1 RNA from the hybridoma secreting MAb 6A.C3 was used as
the template for an RT-PCR to obtain the cDNA encoding the VH module. BamHI and ApaI restriction sites were introduced into VH module cDNA at the 59 and
39 ends, respectively, to facilitate the cloning of the RT-PCR cDNA into pBluescript SK2. Poly(A)1 RNA from porcine hybridoma cells secreting MAb S2.1 of the
IgA isotype was used as the template for an RT-PCR to obtain the cDNA encoding the CH module. ApaI and BamHI restriction sites were introduced into CH module
cDNA at the 59 and 39 ends, respectively, to facilitate the cloning of the RT-PCR-derived cDNA into pBluescript SK2. The resulting VH and CH fragments were joined
at the ApaI restriction site and cloned into the BamHI restriction site of plasmid pING2003E-neo, yielding pINSHC6A. En, SV40 enhancer; Pr, SV40 promoter; An,
poly(A) sequence; pA, SV40 polyadenylation signal.
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with known amounts of restriction enzyme fragments derived from pSS1tgXS
plus BLG-SHC plus BLG-SLC constructs.
Analysis of milk. Milk was collected daily from 4- to 6-month-old lactating
females. The mothers were separated from their pups and 6 h later injected
intraperitoneally (i.p.) with 0.5 to 1 IU of oxytocin (SmithKline Beecham). Milk
was collected with a vacuum pump. Milk samples were diluted 1/10 in 0.125 M
NaCl–25 mM Tris-hydrochloride–5 mM KCl and defatted by centrifugation.
rIgA in the milk was detected by RIA and the neutralization assay. The concen-
tration of rIgA in milk was estimated by RIA with internal standards of purified
rIgA previously quantified with the bicinchoninic acid protein assay reagent
(Pierce, Rockford, Ill.).
RESULTS
Sequence of cDNAs encoding porcine IgA a and k chains.
To enhance antibody stability in the gastrointestinal tract, the
chimeric mouse-human (MH) IgG, with the variable module
from MAb 6A.C3 described previously (11), was engineered to
substitute the constant modules for those from a porcine IgA.
Porcine IgA a and k genes were cloned by RT-PCR with the
mRNA from a porcine hybridoma secreting IgA (24) (Fig. 1).
The cDNA sequence obtained for the CH-module of porcine a
chain (Fig. 3A) showed no changes from the nucleotide se-
quence previously reported for a porcine a chain from a York-
shire gilt (7). The cDNA sequence at the hinge region revealed
that this porcine IgA corresponds to the IgAa allelic form
described recently (8). The cDNA sequence obtained for the
CL module of porcine k chain showed 15 nucleotide changes
(Fig. 3B) in the coding region with respect to the sequence
reported previously for a porcine k chain from an adult Min-
nesota miniature swine (29), leading to 9 changes in the amino
acid sequence. Of the 15 nucleotide changes, 2, at positions 26
and 27 of the C module, have been introduced to create the
ClaI restriction endonuclease site, to facilitate the cloning of
the L-chain gene. In addition, 11 differences were found in the
39 untranslated cDNA sequence. Cysteine residues that usually
participate in intradomain and inter-H-L chain disulfide bonds
were conserved. Similarly, the carboxy-terminal dipeptide after
the last cysteine residue, a unique feature among mammalian
k light chains, was also conserved (29). Both cDNAs encoding
the porcine IgA CH and CL modules contain polyadenylation
signals in the 39 untranslated region.
Generation of rMAb 6A.C3. Construction of the recombi-
nant antibody required the fusion of mouse VL and VH mod-
ules to porcine k and a C modules. This was accomplished by
introducing ClaI or ApaI restriction endonuclease sites into the
Ig genes (Fig. 1). The first 24 nucleotides of the recombinant
CL chain corresponds to the MAb 6A.C3 sequence (mouse CL)
and is joined in frame to the sequence encoding the C module
of the porcine k light chain. A phenylalanine (encoded by
TTC)-to-serine (encoded by TCG) amino acid change at res-
idue 9 of the k C chain was introduced to create the ClaI site
required for the fusion of VL and CL modules. The first 9
nucleotides of the chimeric CH chain corresponds to the mouse
MAb 6A.C3 sequence (mouse CH1) and is joined in frame to
the constant module sequence of porcine a H chain. The
mutagenesis required to create the ApaI restriction site led to
a replacement of the serine present in the original sequence
(encoded by AGC) by a glycine (encoded by GGC), which
corresponds to residue 5 of the CH1 module. cDNAs encoding
recombinant antibody L and H chains were subcloned into
expression plasmids pINSLC6A and pINSHC6A (Fig. 1), re-
spectively, which carry the SV40 early promoter and a mouse
Ig enhancer at the 59 end of the expression cassettes and the
SV40 polyadenylation signals at the 39 end. Sequencing con-
firmed that the V and C Ig modules were correctly joined.
The engineering of rIgG1 with the same V modules as those
of rIgA has been described previously (8).
Physical characterization of rMAbs. The physical structure
of recombinant antibodies, rMH and rMS, secreted by stably
transformed Sp2/0 cells was determined by Western blotting
(Fig. 4). This analysis, performed under nonreducing condi-
tions to study antibody oligomerization (Fig. 4A), demon-
strated that recombinant antibodies with the IgG1 isotype were
monomeric (molecular mass, 150 kDa) while rIgA consisted
mainly of dimeric forms of about 300 kDa and a smaller
amount of monomeric forms. Control IgA secreted by S2.1
porcine hybridoma cells appeared as a mixture of dimeric and
monomeric molecules and a minor proportion of higher poly-
meric forms (Fig. 4A). After reduction of the interchain disul-
fide bonds (Fig. 4B), recombinant IgA and IgG1 dissociate into
the H and L chains, with the expected molecular masses of
FIG. 2. Transgene constructs. (A) Structure of the BLG gene (BLG.SX) indicating the introns deleted to generate the pBJ41 plasmid carrying the intronless BLG
minigene. The ATG present in the BLG gene was removed in pBJ41, and an EcoRV cloning site was created by introducing a linker between exons I and V. Exon
VII does not have an open reading frame. CAAT, TATAA, and AATAAA regulatory signals are indicated. Bold lines indicate 59- and 39-flanking sequences and
intronic sequences of BLG; boxes indicate BLG exon sequences. (B) Grey boxes, VH- or VL- and CHa- or CL-encoding cDNA segments. All constructs comprise
identical 59- and 39-regulatory sequences. Relevant restriction enzyme cutting sites are shown. SP, signal peptide.
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FIG. 3. C domain sequences of porcine k L-chain and a H-chain cDNAs. The sequences of the C Ig domain starting at nucleotide 1 are shown. (A) The nucleotide
sequence of the porcine CHa cDNA domain and the deduced amino acid sequence are shown in the first and second lines, respectively. The ApaI and BamHI cloning
sites introduced at the 59 and 39 ends, respectively, are underlined. Boundaries between domains are indicated by vertical lines and the name of the domain. (B) The
nucleotide sequence of the porcine k L-chain cDNA cloned in our laboratory and the deduced amino acid sequence are shown in the first and third lines, respectively.
In the second and fourth lines, the nucleotide and amino acid substitutions in the sequences previously reported (29) for the porcine k chain are indicated in boldface
type. ClaI and BamHI cloning sites introduced at the 59 and 39 ends, respectively, are underlined. Nucleotides are numbered at both sides of each line. n, cysteine
residues predicted to participate in intradomain disulfide bonds. The polyadenylation signal and the stop codons are shown in boldface type. , absent nucleotides.
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about 60 and 25 kDa, respectively. Recombinant IgA dimers
did not dissociate on treatment with 0.1% SDS and boiling,
suggesting that rIgA molecules could be associated through
covalent interactions. Nevertheless, the association through
noncovalent interactions of a large population of rIgA mole-
cules, in the absence of the Ig J chain, cannot be excluded,
since it has been reported previously that IgA dimers associ-
ated through noncovalent interactions (36). Western blot anal-
ysis under reducing conditions revealed the presence of the Ig
J chain in rIgA dimers (Fig. 4C), indicating that this J chain is
participating in dimer formation by forming disulfide links to a
chains. Although the J chain has a molecular mass of 15 kDa,
the denatured form migrates with an apparent molecular mass
of 26 kDa, in agreement with reported data (56). The minor
bands observed in the IgM lane (Fig. 4C) probably correspond
to the J chain associated with polymeric forms of IgM. The
murine myeloma cell line Sp2/0 synthesizes J chain and thus is
able to assemble and secrete a dimeric rIgA (27).
Functional analysis of recombinant MAbs with a and g1
isotypes. To verify the functionality of rMAb 6A.C3 with IgA
or IgG1 isotypes, COS-1 cells were transiently transfected with
plasmids encoding the chimeric H and L chains. The secreted
chimeric Ig bound TGEV, had RIA titers (i.e., the highest
dilution giving a threefold increase above background) up to
103, and neutralized virus infectivity around 104-fold (i.e., neu-
tralization index 5 4) (Table 1).
Murine Sp2/0 myeloma cells, which did not secrete endog-
enous Igs, were stably transformed by electroporation with
constructs encoding the chimeric H and L chains. Cell trans-
formation frequencies with two genes encoding the H and L Ig
chains ranged between 1023 and 1024 in different experiments.
Binding of the rMAbs to TGEV was determined by RIA with
supernatants from clones secreting the highest antibody levels.
Titers obtained by RIA ranged between 102 and 103 and were
similar to those obtained by transient transfection (Table 1).
Sp2/0 myeloma cells that were transformed with the recombi-
nant mouse-porcine a-chain gene produced the corresponding
H-chain protein but did not secrete this chain into the medium.
Extracts from these cells showed a weak binding to TGEV
(Table 1).
The final aim of this work is to protect newborn piglets
against viral enteric infections through lactogenic immunity.
IgA-isotype antibodies are known to be more stable in mucosal
tissues than are those with an IgG isotype (28). To compare the
neutralizing activities of rIgA and rIgG1, supernatants contain-
ing recombinant antibodies with the same RIA titer were used
in neutralization assays. Recombinant IgA neutralized TGEV
50-fold more efficiently than did rIgG1 when antibody dilutions
with the same titer by RIA were compared, as expected for a
dimeric Ig with respect to a monomeric one (Fig. 5).
Generation of transgenic mice. Analysis of DNA prepared
from tail biopsy specimens showed that 23 of the 93 generation
zero (G0) mice (around 25%) had integrated at least one of the
transgenes (Fig. 6).
Transgene integration in the genome of a modified animal
does not guarantee its expression, since it may be integrated in
a silent chromosome region. It has been previously reported
(11, 12) that it is possible to enhance the efficiency of transgene
expression by cointegrating the expression cassette with a ge-
nomic clone of BLG. This enhancement in transgene expres-
sion (transgene rescue) (12) may be due to the recruitment of
transcription factors into the domain of the chromatin where
the transgene is cointegrated. To help antibody expression,
transgenic mice were produced by coinjection of the BLG gene
with BLG-SLC plus BLG-SHC expression cassettes (BLG1
mice). In all (16 of 16) of the BLG1 transgenic mice (Fig. 6) in
which one or both Ig genes were integrated, the BLG gene was
FIG. 4. Physical characterization of rMAbs. (A and B) Western blot analysis
on 5 to 20% linear gradient SDS-PAGE gels under nonreducing (A) and reduc-
ing (B) conditions, developed with rabbit anti-swine IgA and rabbit anti-mouse
antisera. (C) Western blot analysis performed under reducing conditions devel-
oped with rabbit anti-J-chain antiserum. rIgA, recombinant mouse-swine IgA
produced by transformed Sp2/0 cells. rIgG, recombinant mouse-human IgG.
IgG, MAb 6A.C3 secreted by the original hybridoma cells. IgM, control poly-
meric IgM. The positions of the molecular mass markers expressed in kilodaltons
are indicated on the left.





rIgG-Sp2/0 cells 102–103 102–103
rIgA-Sp2/0 cells 102–103 104
rIgG-COS cells 102–103 104
rIgA-COS cells 103–104 103
ra 5 ,0.3
a Chimeric rIgG1 and rIgA expressed in COS-1 monkey kidney cells and in
Sp2/0 myeloma cells were analyzed by RIA and virus neutralization assays.
MAb-6A.C3, antibody secreted by the original hybridoma. rIgG-Sp2/0 and rIgA-
Sp2/0, recombinant MH and MS antibodies, respectively, secreted by trans-
formed Sp2/0 myeloma cells. rIgG-COS and rIgA-COS, recombinant MH and
MS antibodies, respectively, secreted by transformed COS-1 cells. ra, recombi-
nant mouse-porcine a chain.
b Similar results were obtained in more than five independent evaluations of
the antibodies secreted by the selected cell lines.
c The neutralization index is given. Similar results were obtained in the eval-
uation of more than five independent cultures of transiently transformed COS-1
cells.
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also integrated (data not shown). The integration of expression
cassettes and of genomic BLG was determined by PCR. After
screening more than 250 progeny mice, derived from the 16
founder mice, the cosegregation of Ig and BLG genes was
observed in a high proportion of transgenic animals (.68%),
indicating that in general both Ig and BLG genes had been
integrated in the same chromosomal locus. The majority (17 of
23) of the BLG2 and BLG1 transgenic mice (Fig. 6) had
cointegrated the transgenes encoding the L and H rIgA chains.
Twelve of the BLG1 transgenic mice carrying both H and L
chains had integrated the BLG gene in approximately a 2:1
ratio in relationship to the rIgA genes (data not shown). A
small proportion of transgenic lines (around 25%) had inte-
grated only one of the transgenes. The frequency of integration
of only one of the Ig genes was not significantly modified by the
comicroinjection of the BLG gene.
At least 10 of 17 transgenic founders carrying both SLC and
SHC transmitted both transgenes to their progeny, suggesting
that the genes have been cointegrated in a single site in each
line. One line of transgenic mice (I70) did inherit the trans-
genes at a frequency significantly below 50%, which may indi-
cate mosaicism. The comicroinjection of BLG and Ig genes did
not affect transgene integration (data not shown).
Expression of rIgA in milk. Milk was collected from G0 fe-
males or female progeny of mice which transmitted the trans-
genes for both the H and L genes. rIgA was detected by RIA
in the milk of animals of the two BLG2 transgenic lines, with
titers ranging from 8 3 102 to 3 3 104 (Fig. 7A). Of 12 BLG1
transgenic founders, 8 expressed rIgA in milk (Fig. 7A), with
RIA titers ranging from 5 3 101 to 5 3 106, indicating that the
expression level could be a function of the integration site.
Neutralization assays with milk samples (Fig. 7B) showed
that virus infectivity was reduced around 106-fold with the milk
with the highest titers (mouse C66-374). These results indicat-
ed that the rIgA synthesized in the mammary gland and se-
creted into the milk of transgenic mice was biologically active
in TGEV neutralization.
A significant proportion of the rIgA found in the milk was
oligomeric, as determined by Western blot analysis with por-
cine IgA-specific antisera (results not shown).
No significant differences in transgene expression frequency
were observed between BLG2 and BLG1 transgenic mice (Fig.
6), nor did the cointegration of BLG lead to a significant in-
crease in the antibody expression levels. Nevertheless, the high-
er antibody titers (.106) were obtained in mice that had cointe-
grated Ig and BLG genes (Fig. 7). No detectable levels of rIgA
in the serum of transgenic lines were observed, including the
transgenic females that were actively secreting the recombinant
antibody to the milk with titers higher than 106 (data not shown).
The kinetics of antibody secretion into milk was determined
during lactation (Fig. 8). rIgA levels in the milk of transgenic
mice producing the highest antibody levels (Fig. 8) were sig-
nificant from the first day of lactation, by both RIA and the
TGEV neutralization assay, compared with antibody levels in
wild-type mice (C2). Maximum antibody titers (around 106)
were reached at midlactation (around day 10). The higher
TGEV neutralizing-antibody titer was around 106 and was also
achieved by day 10 of lactation.
The rIgA concentrations in transgenic-mouse milk were
FIG. 5. Comparison of the specific activity of the recombinant antibodies in
TGEV neutralization. The neutralization of TGEV by chimeric rIgG1 and rIgA
antibodies with the same RIA titer is shown. C2, supernatant from myeloma
Sp2/0 cells. F, rIgA; n, rIgG1; }, negative control MAb. The mean and the
standard deviation of three experiments is shown.
FIG. 6. Transmission and expression of transgenes in BLG2 and BLG1 transgenic mice. Transgene integration was screened in tail DNA samples from G0 and G1
mice by PCR with primers detecting the constant L (LC), constant H (HC), and BLG transgenes. PCR-positive samples were further analyzed by Southern blotting
with BLG-specific probes. In several lines, analysis was extended to the G2 and G3 generation of mice. Transgene expression in milk was determined by RIA with G1
females. ND, not determined; NT, no Ig chain transmission; HC, mice which transmitted only the constant H chain.
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measured by RIA with a standard based on purified rIgA; they
ranged from 0.01 to 6 mg/ml. No significant differences in the
antibody expression pattern in the presence or absence of BLG
comicroinjection were observed during lactation (Fig. 8).
The transgene copy number was determined by Southern
blot analysis (Fig. 9). Cleavage of integrated copies with EcoRI
released internal fragments of 6, 5.5, and 4.5 kb for SHC, SLC,
and BLG transgenes, respectively. These three bands were
revealed with a probe specific for the common BLG promoter,
and thus all three genes were detected simultaneously, allow-
ing a comparison of the transgene copy number. The results
were quantified by comparing band intensities for DNA from
tail biopsy specimens with those of known amounts of plasmids
pSS1tgXS, BLG-SHC, and BLG-SLC. A discrete variation in
the transgene copy number (from 2 to 8) was detected in the
transgenic lines analyzed (Fig. 9B), and no correlation was
observed between rIgA expression levels and transgene copy
number (Fig. 9).
The genetic stability of the transgenes was studied for three
successive generations by evaluating the antibody production
in more than 250 transgenic mice. Transgenes segregated as ex-
pected for a single-locus Mendelian character (data not shown).
The rIgA expression levels in milk were constant through the
three generations and were very similar in mice from the same
transgenic line (data not shown). No abnormalities were de-
tected during the development of the antibody producer mice.
The parameters measured to assess the effect of transgene
expression were body weight, progeny number in breedings
through three generations, volume of milk collected, offspring
survival ratio, anatomical observation, and general behavior
(results not shown).
The expression of transgenic IgA in the milk did not signif-
icantly affect the levels of the endogenous mouse Igs, as de-
termined by Western blot analysis (results not shown).
DISCUSSION
A recombinant TGEV neutralizing MAb with porcine IgA
isotype has been engineered. Transgenic mice were construct-
ed that secreted the rIgA MAb into their milk with titers up to
5 3 106, as determined by RIA, and neutralizing 106-fold virus
FIG. 7. Recombinant IgA expression in the milk of transgenic mice. (A) The
RIA titers for rIgA in the milk of BLG2 and BLG1 transgenic mice are shown
as the mean of the antibody titers in three to six milk samples from the same
transgenic mouse, collected at different days through lactation. C2, milk from
nontransgenic mice. (B) Neutralization index of rIgA present in the milk of
BLG2 and BLG1 transgenic lines. The neutralization assays were performed
with same milk samples used for the experiment in panel A.
FIG. 8. rIgA expression in the milk from transgenic mice during lactation.
(A) The titers of rIgA in the milk of transgenic mice I70-454 and C66-374,
generated by microinjecting the Ig chains alone (BLG2) or with the BLG gene
(BLG1), during a lactation cycle are represented. These transgenic mice were
chosen because their milk had the highest RIA titers. C2, milk from a nontrans-
genic mouse. (B) Neutralization index for rIgA in the milk of I70-454 (BLG2)
and C66-374 (BLG1) transgenic mice during lactation.
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infectivity, which should be sufficient to protect against enteric
infections in animals susceptible to TGEV.
Chimeric IgA antibodies are more efficient in virus neutral-
ization than the recombinant antibodies with identical speci-
ficity and IgG isotype, probably because of the tetravalency of
dimeric rIgA (16).
The expression levels of functional TGEV-specific rIgA in
the milk of several transgenic mice (up to 6 mg/ml) are among
the highest expression levels of a complex recombinant protein
in any mammalian expression system, including transgenic
mice (22).
The rIgA expression levels reported in this paper are of the
same order as those found in transgenic mice secreting recom-
binant IgG1 in the mammary gland of transgenic mice (9), and
they clearly fall above the levels of IgA produced in the milk of
nontransgenic mice, which are below 1 mg/ml (38).
rIgA expression levels in the supernatant of stably trans-
formed Sp2/0 cells ranged between 20 and 50 mg/ml; these lev-
els were comparable to the antibody levels produced in other
cell systems (50). rIgA levels obtained in several transgenic
animals are approximately 250-fold higher than in mammalian
cell expression systems. This result was particularly interesting
since it indicated that the epithelial cells of the mammary gland
successfully produced both the H and L Ig chains and provided
the adequate environment for the assembly of a functional IgA
molecule, which implies the formation of a complex with four
protein chains. The dimerization of rIgA molecules by nonco-
valent interactions in the mammary gland cells, lacking J chain,
is anticipated, since previous studies (36) have shown that mo-
nomeric IgA can aggregate to form stable IgA dimers, consist-
ing of a complex with eight protein chains, in the absence of J
chain. The rIgA produced in the milk of transgenic animals
specifically bound and neutralized TGEV, indicating that the
mouse mammary gland tissue performs the adequate post-
translational processing required for the correct assembly of
antibody molecules.
No detectable levels of rIgA in the serum of transgenic lines
were observed, including that of the transgenic females actively
secreting the highest antibody titers into milk. In contrast, in
transgenic mice secreting into the milk rIgG with identical V
modules and titers comparable to those obtained for rIgA,
lower but proportional levels of rIgG were detected in the se-
rum (9). The absence of rIgA in the serum could be explained
by the fact that IgAs, and not IgGs, are recognized by poly-
meric Ig receptors and are transported into secretions by epi-
thelial cells via the receptor-mediated transepithelial transport
system (37). This mechanism would prevent the rIgA from
reaching the systemic circulation, leading to predominant se-
cretion into the milk and mucosal surfaces.
rIgA expression levels in the milk of sows, similar to those
produced by the transgenic mice described in this paper, may
be high enough to protect piglets against TGEV infection.
rIgA contains the V modules of MAb 6A.C3, which very effi-
ciently neutralizes all known TGEV strains and does not lead
to the selection of escape mutants, indicating that it binds to an
essential viral epitope. This fact and the continuous intake of
virus neutralizing recombinant antibodies from the milk of
transgenic sows during lactation should provide in vivo protec-
tion against TGEV infection (52). High levels of rIgA were
detected in the milk of transgenic animals from day 1 of lac-
tation. Furthermore, antibody levels were maintained during
the lactation period, with a maximum reached at midlactation.
If the same expression pattern is maintained in swine, an ef-
fective protection of newborn piglets against TGEV will prob-
ably be achieved.
The comicroinjection of BLG sequences with antibody genes
has not led to a significant increase in the average antibody
expression levels, since in the absence or in the presence of the
BLG gene, approximately the same average antibody titers
were obtained in the milk of transgenic mice. Nevertheless, it
is interesting that maximum antibody expression levels were
obtained when BLG and antibody sequences were comicroin-
jected, although, since a small number of transgenic mice (two
without BLG and nine with BLG) were used, the significance
of BLG cointegration to the attainment of high antibody ex-
pression levels cannot be definitively concluded.
The requirement for introns to achieve an efficient transgene
expression, probably due to the presence of cis-acting ele-
ments, is well documented (6, 10). However, in our system,
cDNAs encoding rIgA H and L chains were inserted into BLG
intronless constructs and an efficient expression of rIgA was
observed in the milk of the transgenic animals, suggesting that
sequences within these cDNAs can also favor expression (53).
One possibility is that some sequences present in the V module
of MAb 6A.C3 L and H chains enhance the expression, since
this MAb has been selected from 2,000 MAb because of its
specificity and high expression level (23). In this context, trans-
gene rescue by comicroinjecting the BLG gene with the trans-
genes (11, 12) may not enhance the efficiency of expression as
dramatically as in those cases with a very inefficient expression
of the intronless transgenes.
No direct relationship between the transgene copy number
and the amount of rIgA protein secreted into the milk was
FIG. 9. Relationship between copy number and rIgA expression in the milk.
(A) Southern blot analysis of BLG2 and BLG1 transgenic lines. C2, nontrans-
genic mouse DNA. Tail DNA samples were cleaved with EcoRI and analyzed by
electrophoresis and Southern blotting. Filters were probed with 59-flanking se-
quences common to the three transgenes. The 6.0-kb BLG-SHC, 5.5-kb BLG-
SLC, and 4.5-kb BLG2 transgene-specific EcoRI fragments are shown. (B)
Comparison of rIgA titers in BLG2 and BLG1 transgenic lines carrying different
transgene copy numbers. The expression levels are reported as the RIA titers.
The RIA titers of rIgA in the milk of BLG2 and BLG1 transgenic mice were
calculated as the mean of the antibody titers in three to six milk samples from the
same mouse.
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observed, suggesting that the site of integration of the trans-
gene has a greater effect on the transcriptional activity than
does gene copy number. Similar results have been obtained by
our laboratory in the expression of this rMAb with the IgG1
isotype under the control of the whey acid protein promoter
(9) and in the expression of other transgenes (53, 54). As when
BLG regulatory sequences were used, antibody expression un-
der whey acid protein control was transgene copy number
independent and was maintained throughout the lactation pe-
riod.
The change in the composition of the milk of transgenic
mice was accompanied by no apparent deleterious side effects,
either to the lactating transgenic females or to the pups suck-
ling their milk. This was expected, since the synthesis of the
rIgA is induced during lactation in the mammary gland and
ceases at the end of the lactation period.
Normal development in the mice secreting high-titer coro-
navirus neutralizing antibodies in the milk was observed, indi-
cating that the production of pathogen-neutralizing antibodies
in the milk could be a useful approach to the prevention of
enteric infections of the newborn.
Ig expression in transgenic animals has been previously re-
ported. The genes encoding the H and L chains were expressed
in lymphoid cells (51). However, the expression was not tem-
porally regulated and association of the endogenous and the Ig
chains was observed. Production of chimeric antibodies in
other tissues that do not synthesize Ig naturally, such as the
mammary gland of transgenic mice, has been reported previ-
ously (32), although the antibody expressed by these transgenic
animals did not have protective activity against infectious
agents and the antibody levels achieved were considerably
lower than the ones reported in this paper.
The modular approach to obtain recombinant antibodies
(i.e., the fusion of V and C Ig domains) described in this paper
could easily be applied to other antibodies with different ther-
apeutic purposes. The secretion of neutralizing MAbs in the
milk of transgenic animals could be applied to improve disease
resistance in livestock and to prevent neonatal infections by a
number of enteric pathogens for which specific MAbs are
available.
The cis-acting sequences determining the mammary expres-
sion of the BLG gene seem to be correctly interpreted in mice,
despite both the absence of an equivalent gene and the species
differences in regulation. An equivalent gene does exist in pigs,
and the results in the murine system may be taken as an
indication that the expression of rIgA under the control of
BLG sequences should also work in pigs, the natural host for
TGEV.
Transgenic swine expressing TGEV neutralizing rIgA are
currently being made by using the same expression cassettes
described in this paper. This new system will allow us to di-
rectly test whether the lactogenic immunity provided by the
transgenic sows to neonates following challenge with TGEV
elicits protection. Since MAbs specific for many viruses infect-
ing the enteric tract are available and since the recombinant
antibodies have been obtained by a modular approach, this
strategy could be the basis of a general procedure to generate
animals resistant to viral infections of the enteric tract.
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